Pathophysiology and Management of Transformed Migraine and Medication Overuse Headache

Christopher J. Boes; David F. Black; David W. Dodick

doi:10.1055/s-2006-939924

Seminars in Neurology, Table of Contents

Semin Neurol 2006; 26(2): 232-241
DOI: 10.1055/s-2006-939924

Pathophysiology and Management of Transformed Migraine and Medication Overuse Headache

Christopher J. Boes¹ , David F. Black¹ , David W. Dodick²

¹Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota
²Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, Arizona

Abstract

ABSTRACT

There is considerable overlap in the mechanisms mediating migraine headache pain and sustained opioid-induced paradoxical pain. Both involve upregulation of calcitonin gene-related peptide and increased excitability of dorsal horn neurons. Descending facilitation from the rostral ventromedial medulla may contribute to this increased excitability. Using special magnetic resonance imaging techniques, high iron levels were found in the periaqueductal gray of patients with chronic daily headache with medication overuse. The periaqueductal gray is the center of a powerful descending antinociceptive neuronal network and projects to the rostral ventromedial medulla and subsequently to the dorsal horn. The periaqueductal gray is also involved in the behavioral response to opiate withdrawal. Dysfunction in the periaqueductal gray may explain why frequent analgesic use can result in medication overuse headache in migraineurs. Management of transformed migraine with medication overuse involves patient education, biobehavioral therapy, withdrawal of overused acute medications, bridge therapy for withdrawal headache, initiation of preventive medication, and close follow-up.

KEYWORDS

Transformed migraine - chronic migraine - medication overuse headache - chronic daily headache

Full Text

References

REFERENCES

1 Boes C J, Capobianco D J. Chronic migraine and medication-overuse headache through the ages. Cephalalgia. 2005; 25 378-390
2 Collier J. Diseases of the nervous system. In: Price FW A Textbook of the Practice of Medicine. London; Hodder and Stoughton 1922: 1502-1506
3 Silberstein S D, Lipton R B, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology. 1996; 47 871-875
4 Silberstein S D, Lipton R B, Solomon S, Mathew N T. Classification of daily and near-daily headaches: proposed revisions to the International Headache Society criteria. Headache. 1994; 34 1-7
5 Headache Classification Subcommittee of the International Headache Society . The international classification of headache disorders, 2nd edition. Cephalalgia. 2004; 24(suppl 1) 1-160
6 Bigal M E, Tepper S J, Sheftell F D, Rapoport A M, Lipton R B. Chronic daily headache: correlation between the 2004 and the 1988 International Headache Society diagnostic criteria. Headache. 2004; 44 684-691
7 Meng I D, Porreca F. Mechanisms of medication overuse headache. Headache Currents. 2004; 1 47-54
8 Bahra A, Walsh M, Menon S, Goadsby P J. Does chronic daily headache arise de novo in association with regular use of analgesics?. Headache. 2003; 43 179-190
9 Welch K MA, Nagesh V, Aurora S K, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?. Headache. 2001; 41 629-637
10 Aurora S K. Imaging chronic daily headache. Curr Pain Headache Rep. 2003; 7 209-211
11 Goadsby P J, Gundlach A L. Localization of 3H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine. Ann Neurol. 1991; 29 91-94
12 Goadsby P J, Knight Y E. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia. 1997; 17 153-158
13 Welch K MA, Goadsby P J. Chronic daily headache: nosology and pathophysiology. Curr Opin Neurol. 2002; 15 287-295
14 Sheftell F D, Brunton S A, Coon T L, Hutchinson S L, Kaniecki R G. Chronic daily headache: understanding and treating a common malady. Family Practice Recertification. 2004; 26 25-36
15 Grazzi L, Andrasik F, D'Amico D et al.. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache. 2002; 42 483-490
16 Kudrow L. Paradoxical effects of frequent analgesic use. In: Critchley M, Friedman A, Goroni S, Sicuteri F Advances in Neurology. New York; Raven Press 1982: 335-341
17 Mathew N T, Kurman R, Perez F. Drug induced refractory headache: clinical features and management. Headache. 1990; 30 634-638
18 Dodick D W. Clinical practice: chronic daily headache. N Engl J Med. 2006; 354 158-165
19 Katsarava Z, Fritsche G, Muessig M, Diener H-C, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001; 57 1694-1698
20 Freitag F G, Lake A, Lipton R, Cady R. on behalf of the US Headache Guidelines Consortium, Section on Inpatient Treatment, Chairpersons: Diamond S Silberstein S . Inpatient treatment of headache: an evidence-based assessment. Headache. 2004; 44 342-360
21 Young W B. Treatment of medication overuse headache and long-term outcome. Headache Currents. 2004; 1 55-59
22 Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener H-C, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005; 25 12-15
23 Mathew N T. Amelioration of ergotamine withdrawal symptoms with naproxen. Headache. 1987; 27 130-133
24 Krymchantowski A V, Barbosa J S. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia. 2000; 20 107-113
25 Pageler L, Katsarava Z, Limmroth V, Diener H-C. Prednisone in the treatment of medication withdrawal headache following medication overuse headache: a placebo-controlled, double-blind and randomized pilot study. Cephalalgia. 2004; 24 792
26 Raskin N H. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986; 36 995-997
27 Boes C J, Jones J M, Dodick D W. A retrospective study of self-administered subcutaneous dihydroergotamine in the outpatient treatment of chronic daily headache associated with medication overuse. Headache. 2000; 40 402
28 Silberstein S D, Schulman E A, Hopkins M M. Repetitive intravenous DHE in the treatment of refractory migraine. Headache. 1990; 30 334-339
29 Silberstein S D, Silberstein J R. Chronic daily headache: long-term prognosis following inpatient treatment with repetitive IV DHE. Headache. 1992; 32 439-445
30 Silberstein S D, Young W B. for the Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology . Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Neurology. 1995; 45 577-584
31 Ford R G, Ford K T. Continuous intravenous dihydroergotamine in the treatment of intractable headache. Headache. 1997; 37 129-136
32 Raskin N H. Modern pharmacotherapy of migraine. Neurol Clin. 1990; 8 857-865
33 Mathew N T, Kailasam J. Repetitive intravenous administration of valproate sodium in intractable migraine: comparison with intravenous dihydroergotamine (DHE). Neurology. 2000; 54(suppl 3) A22
34 Schwartz T H, Karpitskiy V V, Sohn R S. Intravenous valproate sodium in the treatment of daily headache. Headache. 2002; 42 519-522
35 Lu S-R, Fuh J-L, Juang K-D, Wang S-J. Repetitive intravenous prochlorperazine treatment of patients with refractory chronic daily headache. Headache. 2000; 40 724-729
36 Rozen T D. Migraine headache: immunosuppressant therapy. Curr Treat Options Neurol. 2002; 4 395-401
37 Young W B. Medication overuse headache. Curr Treat Options Neurol. 2001; 3 181-188
38 Silberstein S D, Lipton R B, Goadsby P J. Tension-type headache: diagnosis and treatment. In: Silberstein SD, Lipton RB, Goadsby PJ Headache in Clinical Practice. 2nd ed. London; Martin Dunitz 2002: 113-128
39 Redillas C, Solomon S. Prophylactic pharmacological treatment of chronic daily headache. Headache. 2000; 40 83-102
40 Bonuccelli U, Nuti A, Lucetti C, Pavese N, Dell'Agnello G, Muratorio A. Amitriptyline and dexamethasone combined treatment in drug-induced headache. Cephalalgia. 1996; 16 198-200
41 Hering R, Steiner T J. Abrupt outpatient withdrawal of medication in analgesic-abusing migraineurs. Lancet. 1991; 337 1442-1443
42 Krymchantowski A V, Silva M T, Barbosa J S, Alves L A. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache. 2002; 42 510-514
43 Mathew N T. Prophylaxis of migraine and mixed headache: a randomized controlled study. Headache. 1981; 21 105-109
44 Saper J R, Silberstein S D, Lake A E, Winters M E. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache. 1994; 34 497-502
45 Saper J R, Lake A E, Tepper S J. Nefazodone for chronic daily headache prophylaxis: an open-label study. Headache. 2001; 41 465-474
46 Mathew N T, Ali S. Valproate in the treatment of persistent chronic daily headache: an open label study. Headache. 1991; 31 71-74
47 Rothrock J F, Kelly N M, Brody M L, Golbeck A. A differential response to treatment with divalproex sodium in patients with intractable headache. Cephalalgia. 1994; 14 241-244
48 Siva A, Altintas A, Kantarci O et al.. Sodium valproate treatment of chronic daily headache. Cephalalgia. 1997; 17 460-461
49 Freitag F G, Diamond S, Diamond M L, Urban G J. Divalproex in the long-term treatment of chronic daily headache. Headache. 2001; 41 271-278
50 Spira P J, Beran R G. for the Australian Gabapentin Chronic Daily Headache Group . Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology. 2003; 61 1753-1759
51 Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia. 2003; 23 820-824
52 Shuaib A, Ahmed F, Muratoglu M, Kochanski P. Topiramate in migraine prophylaxis: a pilot study. Cephalalgia. 1999; 19 379-380
53 Mathew N T, Kailasam J, Meadors L. Prophylaxis of migraine, transformed migraine, and cluster headache with topiramate. Headache. 2002; 42 796-803
54 Pascual J, Sanchez del Rio M, Mateos V et al.. Topiramate for patients with refractory migraine: an observational, multicenter study in Spain. Neurologia. 2003; 18 364-367
55 Saper J R, Lake A E, Cantrell D T, Winner P K, White J R. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002; 42 470-482
56 Mathew N T. Chronic daily headache. In: Evans RW, Mathew NT Handbook of Headache. 2nd ed. Philadelphia; Lippincott Williams and Wilkins 2005: 113-138
57 Blumenfeld A M, Dodick D W, Silberstein S D. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Dermatol Clin. 2004; 22 167-175
58 Tepper S J, Bigal M E, Sheftell F D, Rapoport A M. Botulinum neurotoxin type A in the preventive treatment of refractory headache: a review of 100 consecutive cases. Headache. 2004; 44 794-800
59 Ondo W G, Vuong K D, Derman H S. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia. 2004; 24 60-65
60 Frishberg B M, Mathew N T, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Neurology. 2005; 64(suppl 1) A422
61 Dodick D W, Mauskop A, Elkind A H, DeGryse R, Brin M F, Silberstein S D. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications (a randomized double-blind, placebo-controlled study). Neurology. 2005; 64(suppl 1) A422
62 Saper J R, Lake A E, Hamel R L et al.. Daily scheduled opioids for intractable head pain: long-term observations of a treatment program. Neurology. 2004; 62 1687-1694
63 Diener H-C, Katasarva Z. Analgesic/abortive overuse and misuse in chronic daily headache. Curr Pain Headache Rep. 2001; 5 545-550

Christopher J BoesM.D.

Department of Neurology, Mayo Clinic College of Medicine

200 First Street SW, Rochester, MN 55906